Table 3.
Censoring events in the analyses for 25% decline in eGFR and ESKD
| Status at the End of Follow-Up | Total | HCV and CKD | CKD Only |
|---|---|---|---|
| 25% decline in eGFR | n=1603 | n=15,1974 | |
| Mean follow-up time in years (SD) | 1.5 (1.6) | 2.5 (2.2) | |
| Event, 25% eGFR decrease | 66,048 (43%) | 915 (57%) | 65,133 (43%) |
| Death | 11,110 (7%) | 113 (7%) | 10,997 (7%) |
| Dialysis | 551 (0.4%) | 50 (3%) | 501 (0.3%) |
| Kidney transplant | 8 (0%) | 0 (0%) | 8 (0%) |
| Liver transplant | 38 (0%) | 14 (1%) | 24 (0%) |
| HCV treatment | 28 (0%) | 28 (2%) | 0 (0%) |
| Disenrollment | 15,445 (10%) | 138 (9%) | 15,307 (10%) |
| End of study, December 31, 2014 | 60,349 (39%) | 345 (22%) | 60,004 (40%) |
| ESKD | n=1534 | n=151,174 | |
| Mean follow-up time in years (SD) | 2.5 (2.3) | 3.7 (2.9) | |
| Event, ESKD | 5402 (4%) | 162 (11%) | 5240 (4%) |
| Death | 29,937 (20%) | 381 (25%) | 29,556 (20%) |
| Dialysis | 74 (0%) | 71 (5%) | 3 (0%) |
| Liver transplant | 71 (0%) | 22 (1%) | 49 (0%) |
| HCV treatment | 37 (0%) | 37 (2%) | 0 (0%) |
| Disenrollment | 21,666 (14%) | 232 (15%) | 21,434 (14%) |
| End of study December 31, 2014 | 95,521 (63%) | 629 (41%) | 94,892 (63%) |
HCV, hepatitis C virus.